GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company

_______________________________________________________________________________________

To Receive daily job alerts, Enter your email address, and dont forget to verify the job alerts:

Delivered by FeedBurner

GlaxoSmithKlineGlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).